Function and mechanism of MCM8 in the development and progression of colorectal cancer

• Published in: Journal of translational medicine Vol. 21; no. 1; pp. 1 - 14
• Main Authors: Yu, Shaojun, Dai, Weixing, Zhao, Senlin, Yang, Yongzhi, Xu, Ye, Wang, Jianwei, Deng, Qun, He, Jinghu, Shi, Debing
• Format: Journal Article
• Language: English
• Published: London BioMed Central Ltd 14.09.2023; BioMed Central; BMC
• Subjects: Analysis; Antibodies; Apoptosis; Cancer; Care and treatment; Cell culture; Cell cycle; Cell growth; CHSY1; Colorectal cancer; Colorectal carcinoma; Development and progression; Genes; Genetic screening; Health aspects; MCM8; Molecular biology; Molecular mechanism; Molecular targeted therapy; Morbidity; Mortality; Patient outcomes; Plasmids; Prognosis; Proteins; Public health; RNA; Therapeutic targets; Tumor promotor; Tumor suppressor genes; Tumorigenesis; Ubiquitination; Wound healing; China
• ISSN: 1479-5876; 1479-5876
• DOI: 10.1186/s12967-023-04084-9

Colorectal cancer (CRC) has become a global health problem which has almost highest morbidity and mortality in all types of cancers. This study aimed to uncover the biological functions and underlying mechanism of MCM8 in the development and progression of CRC. The expression level of MCM8 was found to be upregulated in CRC tissues and significantly associated with tumor grade and patients’ survival. Knocking down MCM8 expression in CRC cells could restrain cell growth and cell motility while promoting cell apoptosis in vitro, as well as inhibit tumor growth in xenograft mice model. Based on the RNA screening performing on CRC cells with or without MCM8 knockdown and the following IPA analysis, CHSY1 was identified as a potential target of MCM8 in CRC, whose expression was also found to be higher in tumor tissues than in normal tissues. Moreover, it was demonstrated that MCM8 may regulate the expression of CHSY1 through affecting its NEDD4-mediated ubiquitination, both of which synergistically execute tumor promotion effects on CRC. In conclusion, the outcomes of our study showed the first evidence that MCM8 act as a tumor promotor in CRC, and may be a promising therapeutic target of CRC treatment.